Inhibition of Aldose Reductase by Gentiana lutea Extracts by Akileshwari, Chandrasekhar et al.
Hindawi Publishing Corporation
Experimental Diabetes Research
Volume 2012, Article ID 147965, 8 pages
doi:10.1155/2012/147965
Research Article
Inhibition of Aldose Reductase by Gentiana lutea Extracts
Chandrasekhar Akileshwari,1 PuppalaMuthenna,1 Branislav Nastasijevic´,2 Gordana Joksic´,2
J. Mark Petrash,3 and Geereddy Bhanuprakash Reddy1
1Biochemistry Division, National Institute of Nutrition, Tarnaka, Jamai-Osmania, Hyderabad 500 007, India
2Vinca Institute of Nuclear Sciences, University of Belgrade, 11001 Belgrade, Serbia
3Department of Ophthalmology, University of Colorado School of Medicine, Aurora, CO 80045, USA
Correspondence should be addressed to Geereddy Bhanuprakash Reddy, geereddy@yahoo.com
Received 3 March 2012; Accepted 22 May 2012
Academic Editor: Subrata Chakrabarti
Copyright © 2012 Chandrasekhar Akileshwari et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Accumulation of intracellular sorbitol due to increased aldose reductase (ALR2) activity has been implicated in the development
of various secondary complications of diabetes. Thus, ALR2 inhibition could be an eﬀective strategy in the prevention or delay of
certain diabetic complications. Gentiana lutea grows naturally in the central and southern areas of Europe. Its roots are commonly
consumed as a beverage in some European countries and are also known to have medicinal properties. The water, ethanol,
methanol, and ether extracts of the roots of G. lutea were subjected to in vitro bioassay to evaluate their inhibitory activity on
the ALR2. While the ether and methanol extracts showed greater inhibitory activities against both rat lens and human ALR2,
the water and ethanol extracts showed moderate inhibitory activities. Moreover, the ether and methanol extracts of G. lutea
roots significantly and dose-dependently inhibited sorbitol accumulation in human erythrocytes under high glucose conditions.
Molecular docking studies with the constituents commonly present in the roots of G. lutea indicate that a secoiridoid glycoside,
amarogentin, may be a potential inhibitor of ALR2. This is the first paper that shows G. lutea extracts exhibit inhibitory activity
towards ALR2 and these results suggest that Gentiana or its constituents might be useful to prevent or treat diabetic complications.
1. Introduction
According to the latest WHO estimates, currently approxi-
mately 200 million people all over the world are suﬀering
from diabetes. This may increase to at least 350 million by
the year 2025, which could have a severe impact on human
health [1]. Prolonged exposure to chronic hyperglycemia
in diabetes can lead to various complications aﬀecting the
cardiovascular, renal, neurological, and visual systems [2].
Although mechanisms leading to diabetic complications are
not completely understood, many biochemical pathways
associated with hyperglycemia have been implicated [2].
Among these, the polyol pathway has been extensively
studied [3].
Aldose reductase (ALR2; EC: 1.1.1.21) belongs to aldo-
keto reductases (AKR) super family. It is the first and rate-
limiting enzyme in the polyol pathway where it reduces
glucose to sorbitol utilizing NADPH as a cofactor. Subse-
quently, sorbitol dehydrogenase catalyzes the conversion of
sorbitol to fructose, thus constituting the polyol pathway [3].
Accumulation of sorbitol leads to osmotic swelling, changes
in membrane permeability, and also oxidative stress culmi-
nating in tissue injury [4]. Experimental animal models
suggest that the inhibition of ALR2 could be eﬀective in
prevention of certain complications [5]. A number of ALR2
inhibitors (ARI) have been developed for diabetic compli-
cations; however, none of them has achieved worldwide use
because of limited eﬃcacy or undesirable side eﬀects [6–9].
Largely, two chemical classes of ARI have been tested in phase
III trials. While carboxylic acid inhibitors (zopolrestat, pon-
alrestat, and tolrestat) have shown poor tissue permeability
and are not very potent in vivo, spiroimide (spirohydantoin)
inhibitors such as sorbinil penetrate tissues more eﬃciently
but many have been associated with skin reactions and liver
toxicity [4, 7, 8, 10]. Thus, there is a need for developing
and evaluating new ARI considering eﬃcacy, selectivity, and
safety issues. We have previously reported, using in vitro,
ex vivo, and in animal models, that some common dietary
sources such as spices, fruits and vegetables have the ARI
potential [11–15].
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Gentiana lutea, commonly known as bitter wort, is a
plant belonging to the family Gentianaceae, which grows
in the grassy alpine and subalpine pastures, usually on
calcareous soils native to the mountains of central and
southern Europe [16]. The roots of G. lutea are commonly
consumed as a beverage in some of the European countries
and are also known to have medicinal properties due to
the presence of bitter glycosides. However, so far ARI
potential of any of the extracts of Gentiana has not been
reported. Therefore, in the present study we have assessed
the ARI potential of various extracts of G. lutea and report
that secoiridoid glycosides and xanthone principles of G.
lutea may be the potent inhibitors of ALR2. Further, these
results are supported by molecular docking studies. We
also investigated the eﬀects of these extracts on intracellular
sorbitol accumulation in red blood cells (RBC) under ex vivo
high glucose conditions which reinforce the ARI potential of
Gentiana.
2. Materials and Methods
2.1. Materials. Ammonium sulphate, D-glucose, DL-
glyceraldehyde, dimethylsulfoxide, EDTA, glycine, lithium
sulphate, 2-mercaptoethanol, methyl orange, NADPH,
NADP, perchloric acid, sorbitol, sorbitol dehydrogenase,
sucrose, and Tris-HCl were obtained from Sigma-Aldrich
(St. Louis, MO). All other chemicals and solvents were of
analytical grade and were obtained from local companies.
2.2. Preparation of G. Lutea Extracts. G. lutea roots used
for ethanol, methanol, ether, and water extracts preparation
were purchased from “Dr. Josif Pancic”, Institute ofMedicinal
Plant Research Belgrade, Serbia. Five grams of dried G. lutea
roots were powdered and extracted with 100mL ofmethanol,
ethanol or ether, at room temperature, for 48 h, with
occasional shaking. After filtering, the extracts were dried
using a rotary evaporator (Buchi R-210/215) at 30–35◦C,
with yield of 37.8% of crude extract for methanol, 4.63%
for ether, 31.76% for ethanol and 18.33% for water. The
stock solutions containing 50mg/mL methanol, 50mg/mL
ethanol, 100mg/mL water and 40mg/mL ether extracts were
prepared immediately before use.
2.3. Separation and Characterization of Extracts from G. lutea.
Chromatographic separations of the extracts were performed
using a BEH C18 column (1.7 µm, 100 × 2.1mm) on a
Waters Acquity UPLC system, equipped with UV visible
detector. Running of extracts was performed in gradient
with mobile phase consisting of solvent (a) trifluoroacetic
acid (0.1% v/v in water) and (b) acetonitrile/methanol
mixture (85 : 15, v/v). The eluent flow rate was 0.3mL
min−1, the injection volume was 10 µL and detection was at
250 nm. MALDI-TOF mass spectra of UPLC fractions were
acquired on a Voyager Biospectrometry DEPro Workstation
(Perseptive Biosystems, Framingham,MA, USA). The system
utilizes a 20Hz pulsed nitrogen laser emitting at 337 nm.
2.4. Preparation of Rat Lens ALR2. Crude ALR2was prepared
from rat lens as described previously [11]. Lenses were
homogenized in 9 volumes of 100mM potassium phosphate
buﬀer, pH 6.2. The homogenate was centrifuged at 15,000×g
for 30min at 4◦C and the resulting supernatant was used as
the source of ALR2.
2.5. Expression and Purification of Recombinant Human
ALR2. Recombinant human ALR2 was overexpressed in
Escherichia coli and purified from bacterial cultures essen-
tially as described previously [14, 17] with a minor modifi-
cation. Chromatography over AﬃGel Blue (Bio-Rad) aﬃnity
matrix was used in final purification step.
2.6. Aldose Reductase (ALR2) Assay. ALR2 activity was
assayed as described previously [11]. The assay mixture
in 1mL contained 50mM potassium phosphate buﬀer,
pH 6.2, 0.4M lithium sulphate, 5mM 2-mercaptoethanol,
10mM DL-glyceraldehyde, 0.1mM NADPH, and enzyme
preparation (rat lens or recombinant enzyme). Appropriate
blanks were employed for corrections. The assay mixture
was incubated at 37◦C and the reaction was initiated
by the addition of NADPH at 37◦C. The change in the
absorbance at 340 nmdue toNADPHoxidation was followed
in a spectrophotometer (Lamda-35, Perkin-Elmer, Shelton,
USA).
2.7. Inhibition Studies. For inhibition studies concentrated
stocks of G. lutea extracts were prepared in water/DMSO.
Various concentrations of these extracts were added to the
ALR2 assay mixture and incubated for 5min before initiating
the reaction by NADPH as described above. The percent
inhibition with test compounds was calculated considering
the ALR2 activity in the absence of inhibitor as 100%. The
concentration of each test sample giving 50% inhibition
(IC50) was determined by nonlinear regression analysis of log
concentration of extract versus percentage inhibition.
2.8. Molecular Docking. Molecular docking was done by dis-
covery (Discover 2.7) package from (Biosystems Technolo-
gies, San Diego, CA, USA), on an O2 (R12000) Workstation
(Silicon Graphics, Mountain View, CA, USA) and GOLD 3.1
(Genetic Optimized for Ligand Docking). All ligands were
minimized and least energy conformations were taken for
docking studies. Crystal structure of ALR2 was downloaded
from Brookhaven data bank (PDB: 1PWM) and protein
structure minimized by using charmM force field. All water
molecules were removed. Docking was done by discovery
ligandfit module in a protein-created sphere of about 12 A˚
around the active site. After docking, poses were viewed by
DS Viewer and PoseView (Biosolve IT) and LigandScout.
2.9. In Vitro Incubation of RBC. Five mL blood was collected
from healthy male volunteers on overnight fasting in hep-
arinized tubes. The study protocols were approved by Insti-
tutional Ethics Committee. Red blood cells were separated
by centrifugation and washed thrice with isotonic saline.
Washed RBC were suspended in Kreb’s-ringer bicarbonate
buﬀer, pH 7.4 (preequilibrated with 5% CO2) and incubated
at 37◦C in presence of 5% CO2 for 3 h under normal
(5.5mM) and high glucose (55mM) conditions [13, 14].
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Gentiopicroside pseudomolecular ion is adduct with Na+.
Table 2: IC50 values for ALR2 inhibition by G. lutea extracts.





Water extract 260± 20 70± 15
Ethanol extract 114± 12 82± 20
Methanol extract 112± 15 23± 5
Ether extract 79± 12 36± 5
Values are mean ± standard deviation of three independent experiments.
The eﬀect of G. lutea extracts on sorbitol accumulation was
evaluated by incubating RBC with diﬀerent concentrations
of extracts.
2.10. Estimation of Sorbitol in RBC. At the end of the incu-
bation period, RBC was homogenized in 9 volumes of 0.8M
perchloric acid. The homogenate was centrifuged at 5,000×g
at 4◦C for 10min and the pH of the supernatant was adjusted
to 3.5 with 0.5M potassium carbonate. The sorbitol content
of the supernatant was measured by fluorometric method as
described previously [18] using a spectrofluorometer (Jasco-
FP 6500, Japan).
3. Results
3.1. Characterization of the Extracts from G. lutea. The
UPLC chromatogram indicated the presence of at least
10 compounds in methanol extract (Figure 1). Partial
characterization of the methanol extract was performed
using MALDI-TOF, after its separation and fractionation
by UPLC. MALDI-TOF analysis of methanol extract indi-
cated the possible presence of the following compounds:
gentisin, bellidifolin-8-O-glucoside, demethylbellidifolin-8-
O-glucoside, isovitexin, swertiamarin, amarogentin, and
gentiopicroside (Table 1). Water extracts were also analyzed
by MS and this confirms the presence of the above-
mentioned compounds characteristic of G. lutea. There was
no evidence of swertisin and demethylbellidifolin presence in
the methanol extract of G. lutea. Gentiopicroside is further
quantified using UPLC-TUV chromatography (retention
time 3.31min) which revealed that its portion in G. lutea
methanol extract was 7.79%. This result is in accordance
with previously published data [19, 20]. However, the other






















Figure 1: UPLC chromatogram of 0.1mg/mL methanol extract of
Gentiana lutea.
important bitter component, amarogentin, was detected only
in traces using MALDI-TOF, since it is present in lower
amount (0.025–0.4%) in the cortex of the root [19, 20].
3.2. Inhibition of ALR2 by G. lutea Extracts. All the four
extracts of G. lutea were tested for their ALR2 inhibitory
potential. The representative inhibition curves of rat and
human recombinant ALR2 are presented in Figure 2, and
the corresponding IC50 values of all the extracts are also
presented in Table 2. Out of these, while aqueous and ethanol
extracts of G. lutea moderately inhibited, the methanol
and ether extracts significantly inhibited rat lens ALR2 and
the recombinant ALR2 (Table 2). The methanol and ether
extracts inhibited rat lens ALR2 with an IC50 value of
112 µg and 79 µg (Figure 2(a)), respectively. In case of human
recombinant ALR2, methanol and ether extract showed an
IC50 value of 23 µg (Figure 2(b)) and 36 µg, respectively.
3.3. Docking Studies. Further, molecular docking studies
were carried out with commonly known constituents of
G. lutea (Table 3). For this, thirteen diﬀerent compounds
selected from various reported studies were used [21–25]
which include some compounds identified from our own
analysis. Among the thirteen compounds, it was observed
that amarogentin showed the highest dock score and possibly
interacts with active site residues His-110, Trp-111, Leu-
300, and Leu-301. It forms hydrogen bond with Trp-20,
His-110, and Leu-300 and hydrophobic interactions with
Trp-219. Based on binding of the ligand, the hydrophobic
specificity pocket exists in open or closed state. It appears
that amarogentin might bind to ALR2 in an open type
of conformation because of formation of hydrogen bond
with Leu-300 (Figure 3). Compared to the well-known
synthetic inhibitor fidarestat which occupied active site of
ALR2 with limited contacts, amarogentin extended into
the hydrophobic cleft called specificity pocket suggesting
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Table 3: Gentiana compounds with their molecular weight and dock score from Accelrys Discovery and GOLD.
S. No Name of the compound Mol. wt Dock score (Discovery) GOLD score
(1) Amarogentin 586.54 59.541 29.84
(2) Gentiopicroside 356.324 57.145 34.20
(3) Swertianolin 436.366 58.277 33.77
(4) Loganic acid 376.355 56.399 13.56
(5) Swertiamarin 374.339 48.984 14.55
(6) Sweroside 358.34 48.773 27.20
(7) Isogentisin 258.22 45.786 34.47
(8) Gentisin 258.22 45.545 31.22
(9) Bellidifolin 274.225 43.528 29.04
(10) Bellidin 260.199 40.144 —
(11) Swertisin 446.404 38.835 —
(12) Gentianine 175.18 37.292 —
(13) Gentianadine 149.146 32.51 —
Table 4: Eﬀect of G. lutea water, methanol and ether extracts on intracellular red cell sorbitol levels.
Group Water extract Methanol extract Ether extract
Control 2.25± 0.016 2.47± 0.22 2.46± 0.25
Glucose 55mM 12.77∗ ± 1.21 11.66∗ ± 1.44 12.16∗ ± 1.08
Glucose 55mM + 10 µg extract 8.85# ± 0.25 8.52# ± 1.04 7.25# ± 0.65
Glucose 55mM + 50 µg extract — 7.43# ± 0.314 5.74# ± 0.69
Glucose 55mM + 100 µg extract 8.15# ± 0.32 — 4.49# ± 0.32
Sorbitol levels are expressed as µg/mL RBC. Sorbitol levels were measured in RBC incubated in the presence of normal (5.5mM) and high (55mM) glucose
for 3 h. ∗indicates a statistically significant diﬀerence from the control group and #indicates a statistically significant diﬀerence from the glucose 55mM group
(P < 0.05). Values are mean ± standard deviation of three independent experiments.
eﬀective inhibition of ALR2. Gentiopicroside, which is one of
the most abundant compounds found in G. lutea roots also
showed similar hydrophobic interactions with Trp-219 but
did not form any hydrogen bond. Therefore, gentiopicroside
binds to ALR2 with the specificity pocket in the closed state
(Figure 4).
3.4. Suppression of Sorbitol Accumulation. Among human
AKRs, ALR2 is unique in its ability to catalyze the NADPH-
dependent conversion of glucose to sorbitol [26]. In addition
to lens, retina, nerve, and kidney, activation of ALR2 in
RBC leads to the accumulation of sorbitol [27]. We have
also found a direct correlation between erythrocyte ALR2
and sorbitol levels [28]. Therefore, we assessed accumulation
of sorbitol in RBC under high glucose conditions (ex vivo)
to understand the significance of in vitro inhibition of
ALR2 by G. lutea, particularly its eﬀect on osmotic stress.
Incubation of RBC with 55mM glucose resulted in the
accumulation of sorbitol about six-fold higher than the
control, whereas presence of all the extracts of G. lutea
under high glucose conditions leads to reduction in the
accumulation of intracellular sorbitol in a dose-dependent
manner (Table 4). While the water extract, G. lutea showed
35% inhibition at a concentration, of 100 µg, the methanol
extract showed similar inhibition at lower concentration that
is, 50 µg. Ether extract at the same concentration (50 µg)
was more eﬀective than the methanol extract in decreasing
sorbitol accumulation by 52%. At 100 µg concentration the
ether extract reduced the intracellular sorbitol accumulation
almost by 63%. These results not only substantiate the
inhibition of ALR2 by G. lutea but also indicate their
significance in terms of preventing the accumulation of
intracellular sorbitol.
4. Discussion
Long-term secondary complications are main cause of
morbidity and mortality in diabetic patients [2]. Several
biochemical mechanisms are involved in the development
of these secondary complications. Activation of polyol
pathway due to increased ALR2 activity is one of the several
mechanisms that have been implicated in the development
of various secondary complications of diabetes. Due to
its proposed involvement in the development of diabetic
complications, ALR2 has been a drug target in the clin-
ical management of secondary complications of diabetes
[29]. Structurally distinct compounds such as flavonoids,
benzopyrans, spirohydantoins, alkaloids, nonsteroidal anti-
inflammatory agents, and quinones have all been shown
to inhibit the enzyme with various degrees of eﬃcacy and
specificity [4, 7]. Sorbinil, statil, tolrestat, alrestatin, epalre-
stat, and ALO1576 are some of the well-studied inhibitors
Experimental Diabetes Research 5
Ether extract, log (µg) 


















Methanol extract, log (µg) 























Figure 2: Representative inhibition plots for Gentiana lutea ether
extract against rat (a) and methanol extract against recombinant
human ALR2 (b). ALR2 activity in the absence of the extract
was considered as 100%. Data are average of three independent
experiments.
that have also been clinically tested. However, to date,
none of the currently available synthetic ARIs have proved
clinically eﬀective and in fact some have had deleterious
side eﬀects. Moreover there is an increased interest in recent
times to identify many natural (plant/spice) sources for their
therapeutic properties, mainly because most of the plant and
plant products are largely free from adverse eﬀects and are
being used as a source of diet and traditional medicine.
The medicinal use of Gentiana has a very long tradition.
The roots and rhizomes of G. lutea showed hepatoprotective
[30], antioxidant [31], and anti-inflammatory activity [32]
and are used as an appetite stimulant [33]. The medicinal
value is due to presence of secoiridoid glycosides and
xanthones located mostly in the cortex of the roots of plants
belonging to the family of Gentianaceae such as Gentianella
and Gentiana [34]. Hence, we have investigated various
extracts of Gentiana for their potential to inhibit ALR2.
Results of the present study showing the inhibition
of ALR2 by the extracts of G. lutea merits attention in
many respects. As shown in Figure 2(a), extracts of G.
lutea inhibited rat lens ALR2, with IC50 values ranging 79–
260 µg/mL. Although rat lens is known to have the highest
ALR2 activity compared to other species, the relevance
of inhibition of rat lens ALR2 by G. lutea extracts may
have limited application to human diabetic complications.
Therefore, we have also assessed the inhibitory potential of
G. lutea extracts against purified human recombinant ALR2
expressed in E. coli. Interestingly extracts ofG. lutea inhibited
human recombinant ALR2 better than that of rat lens ALR2
with IC50 values 23–82 µg/mL (Figure 2(b)). The results with
human ALR2 indicate the potential applicability of Gentiana
extracts with human target. Secondly, the primary structure
of ALR2 displays high similarities with closely related
members of AKR superfamily such as human small intestine
reductase (HSIR) or AKR1B10. Therefore we next studied
the specificity of methanol extract with AKR1B10 and
showed its marked specificity towards ALR2 over AKR1B10.
Though the ether extract inhibited AKR1B10, the IC50 value
was ten times higher than ALR2 (400 ± 10µg), indicating
its relative selectivity for ALR2. Also, suppression of sorbitol
accumulation in human erythrocytes under high glucose
conditions by these extracts is suggestive of translating its
impact to in vivo conditions.
Although the beneficial impact of strict glycemic control
on prevention of diabetic complications has been well
established, most individuals with diabetes rarely achieve
consistent euglycemia. However, the eﬀects of Gentiana
on glycemic control (hypoglycemic and antidiabetic) have
not been reported and studies are underway to investigate
its hypoglycemic potential. Nevertheless, agents that can
substantially delay or prevent the onset and development
of diabetic complications, irrespective of glycemic control,
would oﬀer many advantages. In principle, ARI can be
included in this category. Thus, intensive research continues
to identify and test both synthetic as well as natural
products for their therapeutic value to prevent the onset
and/or delay progression of diabetic complications. The
results of the present study are a step forward in this
direction.
5. Conclusions
In conclusion, for the first time we report that extracts of
G. lutea roots inhibit human recombinant ALR2 in vitro and
this inhibition appears to be relatively specific towards ALR2
over HSIR. Although, the in vitro results per se may have
limited implication, these findings provide the directions for
exploring the prospects of Gentiana extracts to prevent or
treat diabetic complications. Therefore, further studies are
needed to corroborate these findings in animal models.
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Figure 3: Stereoview of ALR2 docked with amarogentin. (a) Amarogentin docked into the active site of ALR2 and extended towards
hydrophobic pocket. (b) Amarogentin docked into active site of ALR2 and depicts its hydrogen bond interaction with residues Trp-20,














Figure 4: Stereoview of ALR2 docked with gentiopicroside. (a) Gentiopicroside docked into the active site of ALR2 and extended towards
hydrophobic pocket. (b) Gentiopicroside docked into active site of ALR2 and depicts its hydrophobic interactions with Trp-219, Phe-122,
and Leu-301 (dotted line).
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